Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) Net Margin (2017 - 2025)

Arcus Biosciences has reported Net Margin over the past 9 years, most recently at 321.21% for Q4 2025.

  • Quarterly results put Net Margin at 321.21% for Q4 2025, up 4033.0% from a year ago — trailing twelve months through Dec 2025 was 142.91% (down 3323.0% YoY), and the annual figure for FY2025 was 142.91%, down 3323.0%.
  • Net Margin for Q4 2025 was 321.21% at Arcus Biosciences, up from 519.23% in the prior quarter.
  • Over the last five years, Net Margin for RCUS hit a ceiling of 78.83% in Q4 2021 and a floor of 824.17% in Q3 2021.
  • Median Net Margin over the past 5 years was 320.0% (2023), compared with a mean of 355.24%.
  • Peak annual rise in Net Margin hit 177268bps in 2021, while the deepest fall reached -82700bps in 2021.
  • Arcus Biosciences' Net Margin stood at 78.83% in 2021, then crashed by -350bps to 197.06% in 2022, then plummeted by -194bps to 578.57% in 2023, then surged by 38bps to 361.54% in 2024, then increased by 11bps to 321.21% in 2025.
  • The last three reported values for Net Margin were 321.21% (Q4 2025), 519.23% (Q3 2025), and 400.0% (Q1 2025) per Business Quant data.